Management of endometrial cancer

Obstetrics and Gynecology

Volumn 106, Issue 2, 2005, Pages 413-425

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; GESTAGEN;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CELL TYPE; COMPUTER ASSISTED TOMOGRAPHY; COST OF ILLNESS; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; ENDOMETRIUM CANCER; HUMAN; HYSTERECTOMY; LYMPH NODE METASTASIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK REDUCTION; TREATMENT PLANNING; ARTICLE; ENDOMETRIUM TUMOR; FEMALE; PRACTICE GUIDELINE;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS;

EID: 22544448651     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006250-200508000-00050     Document Type: Review

References (82)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30. (Level II-3)
2. Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz AP, et al. Carcinoma of the corpus uteri. Int J Gynaecol Obstet 2003;83(Suppl 1):79-118. (Level II-3)
3. Ries LA, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al, editors. SEER Cancer Statistics Review, 1975-2001, National Cancer Institute. Bethesda (MD): 2004. Available at: http://seer.cancer.gov/csr/1975_2001/. Retrieved November 9, 2004. (Level II-3)
4. Gershenson DM, McGuire WP, Gore M, Quinn MA, Thomas G, editors. Gynecologic cancer: controversies in management. Philadephia (PA): Elsevier; 2004. (Level III)
5. Boyd J. Hereditary gynecology cancer syndromes. In: Gershenson DM, McGuire WP, Gore M, Quinn MA, Thomas G, editors. Gynecologic cancer: controversies in management. Philadephia (PA): Elsevier; 2004. p. 833-45. (Level III)
6. Alberhasky RC, Connelly PJ, Christopherson WM. Carcinoma of the endometrium. IV. Mixed adenosquamous carcinoma. A clinical-pathological study of 68 cases with long-term follow-up. Am J Clin Pathol 1982;77: 655-64. (Level III)
7. Pekin T, Yildizhan B, Eren F, Pekin O, Yildizhan R. Adenocarcinoma, adenoacanthoma, and mixed adenosquamous carcinoma of the endometrium. Eur J Gynaecol Oncol 2001;22:151-3. (Level III)
8. Zaino RJ, Kurman R, Herbold D, Gliedman J, Bundy BN, Voet R, et al. The significance of squamous differentiation in endometrial carcinoma. Data from a Gynecologic Oncology Group study. Cancer 1991;68:2293-302. (Level II-2)
9. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985;56:403-12. (Level III)
10. Trimble CL. Atypical endometrial hyperplasia: a tough call. Int J Gynecol Cancer 2005;15:401.
11. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-30. (Level III)
12. Maxwell GL, Risinger JI, Gumbs C, Shaw H, Bentley RC, Barrett JC, et al. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res 1998;58: 2500-3. (Level III)
13. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-108. (Level III)
14. Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium: I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma. Cancer 1982;49:1511-23. (Level III)
15. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991;40:55-65. (Level II-2)
16. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60(Suppl 8):2035-41. (Level II-2)
17. Boronow RC, Morrow CP, Creasman WT, Disaia PJ, Silverberg SG, Miller A, et al. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol 1984;63:825-32. (Level III)
18. Kodama S, Kase H, Tanaka K, Matsui K. Multivariate analysis of prognostic factors in patients with endometrial cancer. Int J Gynaecol Obstet 1996;53:23-30. (Level II-3)
19. Baak JP, Snijders WP, Van Diest PJ, Armee-Horvath E, Kenemans P. Confirmation of the prognostic value of the ECPI-1 score (myometrial invasion, DNA-ploidy and mean shortest nuclear axis) in FIGO stage I endometrial cancer patients with long follow-up. Int J Gynecol Cancer 1995;5:112-6. (Level II-2)
20. Ambros RA, Kurman RJ. Identification of patients with stage I uterine endometrioid adenocarcinoma at high risk of recurrence by DNA ploidy, myometrial invasion, and vascular invasion. Gynecol Oncol 1992;45:235-9. (Level II-3)
21. Gal D, Recio FO, Zamurovic D, Tancer ML. Lymph vascular space involvement - a prognostic indicator in endometrial adenocarcinoma. Gynecol Oncol 1991; 42:142-5. (Level II-3)
22. American Joint Committee on Cancer. AJCC cancer staging manual. 6th ed. New York (NY): Springer-Verlag; 2002. (Level III)
23. Patsner B, Tenhoppen DJ, Mann WJ. Use of serum CA-125 levels to monitor therapy of patients with advanced or recurrent endometrial carcinoma. Eur J Gynaecol Oncol 1989;10:322-5. (Level III)
24. Patsner B, Orr JW Jr, Mann WJ Jr. Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma. Am J Obstet Gynecol 1990;162: 427-9. (Level II-2)
25. Kilgore LC, Partridge EE, Alvarez RD, Austin JM, Shingleton HM, Noojin F 3rd, et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 1995; 56:29-33. (Level II-3)
26. Giradi F, Petra E, Heydarfadai M, Haas J, Winter R. Pelvic lymphadenectomy in the surgical treatment of endometrial cancer. Gynecol Oncol 1993;49:177-80. (Level III)
27. Chuang L, Burke TW, Tornos C, Marino BD, Mitchell MF, Tortolero-Luna G, et al. Staging laparotomy for endometrial carcinoma: assessment of retroperitoneal lymph nodes. Gynecol Oncol 1995;58:189-93. (Level II-3)
28. Arango HA, Hoffman MS, Roberts WS, DeCesare SL, Fiorica JV, Drake J. Accuracy of lymph node palpation to determine need for lymphadenectomy in gynecologic malignancies. Obstet Gynecol 2000;95:553-6. (Level II-3)
29. McMeekin DS, Lashbrook D, Gold M, Johnson G, Walker JL, Mannel R. Analysis of FIGO Stage III endometrial cancer patients. Gynecol Oncol 2001;81:273-8. (Level II-3)
30. Geisler JP, Geisler HE, Melton ME, Wiemann MC. What staging surgery should be performed on patients with uterine papillary serous carcinoma? Gynecol Oncol 1999;74:465-7. (Level II-3)
31. Orr JW Jr, Orr PF, Taylor PT. Surgical staging endometrial cancer. Clin Obstet Gynecol 1996;39:656-68. (Level III)
32. Kennedy AW, Austin JM Jr, Look KY, Munger CB. The Society of Gynecologic Oncologists Outcomes Task Force. Study of endometrial cancer: initial experiences. Gynecol Oncol 2000;79:379-98. (Level III)
33. Holub Z, Jabor A, Bartos P, Eim J, Urbanek S, Pivovarnikova R. Laparoscopic surgery for endometrial cancer: long-term results of a multicentric study. Eur J Gynaecol Oncol 2002;23:305-10. (Level II-2)
34. Eltabbakh GH, Shamonki MI, Moody JM, Garafano LL. Laparoscopy as the primary modality for the treatment of women with endometrial carcinoma. Cancer 2001;91: 378-87. (Level II-2)
35. Malur S, Possover M, Michels W, Schneider A. Laparoscopic-assisted vaginal versus abdominal surgery in patients with endometrial cancer - a prospective randomized trial. Gynecol Oncol 2001;80:239-44. (Level I)
36. Fanning J, Hoffman ML, Andrews SJ, Harrah AW, Feldmeier JJ. Cost-effectiveness analysis of the treatment for intermediate risk endometrial cancer: postoperative brachytherapy vs. observation. Gynecol Oncol 2004; 93:632-6. (Level III)
37. Straughn JM, Huh WK, Orr JW Jr, Kelly FJ, Roland PY, Gold MA, et al. Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy. Gynecol Oncol 2003;89:295-300. (Level II-3)
38. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Surgery and post-operative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355:1404-11. (Level I)
39. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 1980;56:419-27. (Level II-2)
40. Creutzberg CL, van Putten WL, Warlam-Rodenhuis CC, van den Bergh AC, de Winter KA, Koper PC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 2004;22:1234-41. (Level II-2)
41. Mariani A, Webb MJ, Keeney GL, Aletti G, Podratz KC. Predictors of lymphatic failure in endometrial cancer. Gynecol Oncol 2002;84:437-42. (Level II-3)
42. Nelson G, Randall M, SuttonG, Moore D, Hurteau J, Look K. FTGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy. Gynecol Oncol 1999;75:211-4. (Level II-3)
43. Fanning J. Treatment for early endometrial cancer. Cost-effectiveness analysis. J Reprod Med 1999;44:719-23. (Level III)
44. Childers JM, Spirtos NM, Brainard P, Surwit EA. Laparoscopic staging of the patient with incompletely staged early adenocarcinoma of the endometrium. Obstet Gynecol 1994;83:597-600. (Level III)
45. Mundt AJ, McBride R, Rotmensch J, Waggoner SE, Yamada SD, Connell PP. Significant pelvic recurrence in high-risk pathologic stage I-IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:1145-53. (Level II-3)
46. Ayhan A, Taskiran C, Celik C, Aksu T, Yuce K. Surgical stage III endometrial cancer: analysis of treatment outcomes, prognostic factors and failure patterns. Eur J Gynaecol Oncol 2002;23:553-6. (Level II-3)
47. Bristow RE, Zahurak ML, Alexander CJ, Zellars RC, Montz FJ. FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival. Int J Gynecol Cancer 2003;13:664-72. (Level II-3)
48. Rose PG, Cha SD, Tak WK, Fitzgerald T, Reale F, Hunter RE. Radiation therapy for surgically proven para-arotic node metastasis in endometrial carcinoma. Int J Radiat Oncol Biol Phys 1992;24:229-33. (Level II-3)
49. Husseinzadeh N, Shrake P, DeEulis T, Rowley K, Aron B. Chemotherapy and extended-field radiation therapy to para-aortic area in patients with histologically proven metastatic cervical cancer to para-artic nodes: a phase II pilot study. Gynecol Oncol 1992:326-31. (Level I)
50. Katz LA, Andrews SJ, Fanning J. Survival after multi-modality treatment for stage IIC endometrial cancer. Am J Obstet Gynecol 2001;184:1071-3. (Level II-2)
51. McMeekin DS, Tillmanns T. Endometrial cancer: treatment of nodal metastases. Curr Treat Options Oncol 2003;4:121-30. (Level III)
52. Memarzadeh S, Holschneider CH, Bristow RE, Jones NL, Fu YS, Karlan BY, et al. FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival. Int J Gynecol Cancer 2002;12:454-8. (Level II-3)
53. Ayhan A, Taskiran C, Celik C, Yuce K, Kucukali T. The influence of cytoreductive surgery on survival and morbidity in stage IVB endometrial cancer. Int J Gynecol Cancer 2002;12:448-53. (Level II-3)
54. Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol 2000;78:85-91. (Level II-3)
55. Chi DS, Welshinger M, Venkatraman ES, Barakat RR. The role of surgical cytoreduction in Stage IV endometrial carcinoma. Gynecol Oncol 1997;67:56-60. (Level II-3)
56. Goff BA, Goodman A, Muntz HG, Fuller AF Jr, Nikrui N, Rice LW. Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol Oncol 1994;52:237-40. (Level II-3)
57. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004;22:2159-66. (Level I)
58. Leminen A, Forss M, Lehtovirta P. Endometrial adenocarcinoma with clinical evidence of cervical involvement: accuracy of diagnostic procedures, clinical course, and prognostic factors. Acta Obstet Gynecol Scand 1995;74: 61-6. (Level II-3)
59. Boente MP, Orandi YA, Yordan EL, Miller A, Graham JE, Kirshner C, et al. Recurrence patterns and complications in endometrial adenocarcinoma with cervical involvement. Ann Surg Oncol 1995;2:138-44. (Level II-3)
60. Maggino T, Romagnolo C, Landoni F, Sartori E, Zola P, Gadducci A. An analysis of approaches to the management of endometrial cancer in North America: a CTF study. Gynecol Oncol 1998;68:274-9. (Level III)
61. Mariani A, Webb MJ, Kenney GL, Calori G, Podratz KC. Role of wide/radical hysterectomy and pelvic lymph node dissection in endometrial cancer with cervical involvement. Gynecol Oncol 2001;83:72-80. (Level II-3)
62. Sartori E, Gadducci A, Landoni F, Lissoni A, Maggino T, Zola P, et al. Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy. Int J Gynecol Cancer 2001;11:430-7. (Level II-3)
63. Reisinger SA, Staros EB, Mohiuddin M. Survival and failure analysis in stage II endometrial cancer using the revised 1988 FIGO staging system. Int J Radiat Oncol Biol Phys 1991;21:1027-32. (Level II-3)
64. Maingon P, Horiot JC, Fraisse J, Salas S, Collin F, Bone-Lepinoy MC, et al. Preoperative radiotherapy in stage I/II endometrial adenocarcinoma. Radiother Oncol 1996;39: 201-8. (Level II-3)
65. Eltabbakh GH, Moore AD. Survival of women with surgical stage II endometrial cancer. Gynecol Oncol 1999; 74:80-5. (Level II-3)
66. Calvin DP, Connell PP, Rotmensch J, Waggoner S, Mundt AJ. Surgery and postoperative radiation therapy in stage II endometrial carcinoma. Am J Clin Oncol 1999;22: 338-43. (Level II-3)
67. Fishman DA, Roberts KB, Chambers JT, Kohorn EI, Schwartz PE, Chambers SK. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium. Gynecol Oncol 1996;61:189-96. (Level II-2)
68. Kucera H, Knocke TH, Kucera E, Potter R. Treatment of endometrial carcinoma with high-dose-rate brachytherapy alone in medically inoperable stage I patients. Acta Obstet Gynecol Scand 1998;77:1008-12. (Level II-3)
69. Rouanet P, Dubois JB, Gely S, Pourquier H. Exclusive radiation therapy in endometrial carcinoma. Int J Radiat Oncol Biol Phys 1993;26:223-8. (Level II-3)
70. Knocke TH, Kucera H, Weidinger B, Holler W, Potter R. Primary treatment of endometrial carcinoma with high-dose rate brachytherapy: results of 12 years of experience with 280 patients. Int J Radiat Oncol Biol Phys 1997; 37:359-65. (Level II-3)
71. Kupelian PA, Eifel PJ, Tornos C, Burke TW, Delclos L, Oswald MJ. Treatment of endometrial carcinoma with radiation therapy alone. Int J Radiat Oncol Biol Phys 1993;27:817-24. (Level II-3)
72. Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 2002;186:651-7. (Level III)
73. Gotlieb WH, Beiner ME, Shalmon B, Korach Y, Segal Y, Zmira N, et al. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol 2003;102:718-25. (Level III)
74. Imai M, Jobo T, Sato R, Kawaguchi M, Kuramoto H. Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus - usefulness and limitations. Eur J Gynaecol Oncol 2001;22:217-20. (Level III)
75. Kaku T, Yoshikawa H, Tsuda H, Sakamoto A, Fukunaga M, Kuwabara Y, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett 2001;167:39-48. (Level III)
76. Wang CB, Wang CJ, Huang HJ, Hsueh S, Chou HH, Soong YK, et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. Cancer 2002;94:2192-8. (Level III)
77. Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 2004;95:133-8. (Level III)
78. Tillmanns TD, Kamelle SA, Abudayyeh I, McMeekin SD, Gold MA, Korkos TG, et al. Panniculectomy with simultaneous gynecologic oncology surgery. Gynecol Oncol 2001;83:518-22. (Level III)
79. Scribner DR Jr, Walker JL, Johnson GA, McMeekin SD, Gold MA, Mannel RS. Surgical management of early-stage endometrial cancer in the elderly: is laparoscopy feasible? Gynecol Oncol 2001;83:563-8. (Level II-3)
80. Bloss JD, Berman ML, Bloss LP, Buller RE. Use of vaginal hysterectomy for the management of stage I endometrial cancer in the medically compromised patient. Gynecol Oncol 1991;40:74-7. (Level II-3)
81. Aalders JG, Abeler V, Kolstad P. Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol 1984;17:85-103. (Level II-2)
82. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study [published erratum appears in Gynecol Oncol 2004;94:241-2]. Gynecol Oncol 2004;92:744-51. (Level I)